Study eligibility criteria of the SLR
| Criteria . | Inclusion criteria . | Exclusion criteria . |
|---|---|---|
| Population | •Humans with CVID | •Studies with ≤10 patients (unless intervention was described) |
| •Animal studies | ||
| •In vitro studies | ||
| Interventions/comparators | •No restriction, as long as noninfectious, nonmalignant manifestations were reported | |
| Outcomes | •Description of the clinical profile of patients, including: | •Studies focused on vaccine response or IRT |
| o Median age and range of symptom onset (including for individual immune dysregulation manifestations when reported) and CVID diagnosis (separating pediatric and adult patients when reported) | ||
| o Genetic diagnoses | ||
| o Frequency of patients with: | ||
| Distinct immune dysregulation manifestations | ||
| Infections | ||
| Other reported manifestations | ||
| o Mortality and causes of death | ||
| •Description of the current treatment landscape for patients with CVID, including treatment agents and responses | ||
| Study design | •Randomized controlled trials | •SLRsa |
| •Nonrandomized clinical trials (e.g., single-arm trials) | •Narrative reviews | |
| •Prospective and retrospective observational studies | •Letters to editor, notes, and editorials | |
| •Case-control studies | •Case reports and case series (unless intervention was described) | |
| Publication type | •Full-text publications | |
| •Conference abstracts/postersb | | |
| Language | •Studies published in English only | |
| Time | •No time restriction | |
| Criteria . | Inclusion criteria . | Exclusion criteria . |
|---|---|---|
| Population | •Humans with CVID | •Studies with ≤10 patients (unless intervention was described) |
| •Animal studies | ||
| •In vitro studies | ||
| Interventions/comparators | •No restriction, as long as noninfectious, nonmalignant manifestations were reported | |
| Outcomes | •Description of the clinical profile of patients, including: | •Studies focused on vaccine response or IRT |
| o Median age and range of symptom onset (including for individual immune dysregulation manifestations when reported) and CVID diagnosis (separating pediatric and adult patients when reported) | ||
| o Genetic diagnoses | ||
| o Frequency of patients with: | ||
| Distinct immune dysregulation manifestations | ||
| Infections | ||
| Other reported manifestations | ||
| o Mortality and causes of death | ||
| •Description of the current treatment landscape for patients with CVID, including treatment agents and responses | ||
| Study design | •Randomized controlled trials | •SLRsa |
| •Nonrandomized clinical trials (e.g., single-arm trials) | •Narrative reviews | |
| •Prospective and retrospective observational studies | •Letters to editor, notes, and editorials | |
| •Case-control studies | •Case reports and case series (unless intervention was described) | |
| Publication type | •Full-text publications | |
| •Conference abstracts/postersb | | |
| Language | •Studies published in English only | |
| Time | •No time restriction | |